Jay R. Luly
Known title: President and CEOCIK: 0001571211
Jay R. Luly's purchase track record
Jay R. Luly has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/12/2025 | ENTA | $256K | -11.6% | +29.3% | +6.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ENTA | ▲ Buy | Grant | 4,800 | $0 | 2/12/2026 | View on chart |
| ENTA | ▲ Buy | Grant | 15,200 | $0 | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 6,155 | $88K | 2/12/2026 | View on chart |
| ENTA | ▼ Sell | Open Market | 4,743 | $67K | 12/5/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 1,885 | $27K | 12/1/2025 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 7,484 | $42K | 2/12/2025 | View on chart |
| ENTA | ▲ Buy | Open Market | 45,000 | $256K | 2/12/2025 | View on chart |
| ENTA | ▲ Buy | Grant | 25,500 | $0 | 2/12/2025 | View on chart |
| ENTA | ▼ Sell | Open Market | 5,142 | $41K | 12/6/2024 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 3,829 | $33K | 12/1/2024 | View on chart |
| ENTA | ▲ Buy | Grant | 5,400 | $0 | 2/12/2024 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 1,584 | $20K | 2/12/2024 | View on chart |
| ENTA | ▼ Sell | Open Market | 7,230 | $70K | 12/5/2023 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 5,787 | $55K | 12/1/2023 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 27,912 | $391K | 3/13/2023 | View on chart |
| ENTA | ▼ Sell | Open Market | 10,697 | $479K | 3/13/2023 | View on chart |
| ENTA | ▼ Sell | Open Market | 1,566 | $72K | 3/13/2023 | View on chart |
| ENTA | ▼ Sell | Open Market | 15,649 | $709K | 3/13/2023 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 20,591 | $1.1M | 2/13/2023 | View on chart |
| ENTA | ▲ Buy | Grant | 15,285 | $0 | 2/13/2023 | View on chart |
| ENTA | ▲ Buy | Grant | 16,220 | $0 | 2/13/2023 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 14,500 | $400K | 12/19/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 13,603 | $619K | 12/16/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 8,597 | $383K | 12/16/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 13,851 | $194K | 12/16/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 16,149 | $229K | 12/16/2022 | View on chart |
| ENTA | ▼ Sell | Open Market | 7,800 | $340K | 12/16/2022 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 5,659 | $251K | 12/1/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 63,000 | $0 | 11/23/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 1,627 | $0 | 2/14/2022 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 2,355 | $147K | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Grant | 6,401 | $0 | 2/14/2022 | View on chart |
| ENTA | ▲ Buy | Option Exercise | 10,063 | $118K | 1/15/2022 | View on chart |
| ENTA | ▼ Sell | Tax Withholding | 1,944 | $170K | 12/1/2021 | View on chart |
| ENTA | ▲ Buy | Grant | 25,700 | $0 | 11/19/2021 | View on chart |
| ENTA | ▼ Sell | Open Market | 4,516 | $267K | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
HC Wainwright Maintains $20 Target for Enanta
HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.
HC Wainwright Maintains $20 Target for Enanta. HC Wainwright reiterated its stance on Enanta Pharmaceuticals, keeping a price target of $20. This view aligns with the broader analyst consensus, where the average target across six analysts is $21.83. The stock is currently trading near its 52-week low, with recent technical signals indicating support at $13.25.